Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient in ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara ®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire ...

A synthetic form of the active ingredient in magic mushrooms has cleared an early-phase trial. The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any ...

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has joined the Psychiatry Consortium, an ...

Compass Pathways Plc., a U.K. startup backed by tech billionaire Peter Thiel and lead investor Christian Angermayer, has filed to go public about four years after it was founded to explore the use of ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025. CTX-10726 (a novel PD-1 x ...

Welcome to State of Mind, a new section from Slate and Arizona State University dedicated to exploring mental health. Follow us on Twitter. Psychedelic drugs are still classified as Schedule 1 drugs, ...

(Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug ...